David Lebowitz from Citi has maintained a Buy rating on Ascendis Pharma (ASND), with a price target of $200.00, based on the company's promising clinical trial results and future growth prospects. The positive outcomes from the trial of TransCon hGH for treating Turner Syndrome highlight the drug's potential effectiveness and safety, suggesting its applicability could extend beyond growth hormone deficiency to include genetic forms of short stature.
Skytrofa, the commercial name for TransCon hGH, is already approved for pediatric growth hormone deficiency, with an approval for adult growth hormone deficiency anticipated by July 2025. Additionally, plans to initiate a basket trial for various growth hormone indications in the first half of 2025 support expectations of a significant share price return of 54.0%. These factors contribute to Lebowitz's optimistic outlook on Ascendis Pharma, leading to a Buy rating despite the high-risk classification.
Jefferies also maintained a Buy rating on the stock with a $194.00 price target in a separate report. Ascendis Pharma A/S, founded in September 2006 and headquartered in Hellerup, Denmark, is a biopharmaceutical company that develops drug candidates through its TransCon technology, focusing on sustained release prodrug therapies including endocrinology product candidates.
